ٹیگ: mineralocorticoid receptor antagonist

For decades, the mainstays of kidney protection in diabetes have been ACE inhibitors and ARBs. Recently, a new class of medication has emerged as a powerful tool: non-steroidal mineralocorticoid receptor antagonists (MRAs), with the leading drug being finerenone (brand name Kerendia). What is Finerenone and How Does it Work? Finerenone works differently from SGLT2 inhibitors…